|
7 type III and 1 patient 3 stromectol for animals When we analyzed the responses according to the time between the first recurrence and entry into the study, there was no difference at all when this period was more than six months 4 of 12 patients in the dacarbazine group had responses, as compared with 3 of 12 in the dacarbazine plus tamoxifen group, whereas the difference in favor of dacarbazine plus tamoxifen was statistically significant when this period was six months or less 14 of 48 patients 29 percent in the dacarbazine plus tamoxifen group vs |
|